Aktie A1JM5T SUVEN LIFE SCIENCES LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Suven Life Sciences Limited

Aktien

A1JM5T

INE495B01038

SUVEN

Verzögert Bombay S.E.
Andere Börsenplätze
 09:55:56 27.06.2024 		% 5 Tage % 1. Jan.
103,6 INR +0,51 % Intraday Chart für Suven Life Sciences Limited +4,65 % +28,47 %
06.05. Suven Life Sciences Limited meldet die Ergebnisse für das am 31. März 2024 endende Geschäftsjahr CI
06.05. Suven Life Sciences Limited meldet Gewinnergebnisse für das vierte Quartal bis zum 31. März 2024 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Suven Life Sciences : June 03, 2024Suven Life Sciences to Present New Data Analyses from Samelisant Positive Phase-2 Study Results at t
Suven Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024
Suven Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA
Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA
Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024
Suven Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Suven Life Sciences : October 30, 2023Suven Life Sciences announces Positive Topline Results from a Phase-2 study evaluating Samelisant
Suven Life Sciences Announces Positive Topline Results from A Phase-2 Study Evaluating Samelisant (SUVN-G3031) for Excessive Daytime Sleepiness in Adult Narcolepsy Patients with and Without Cataplexy
October 24, 2023Suven Life Sciences Announces Scientific Presentation at CTAD-2023: Study Design of Global Phase-3
Suven Pharma Appoints New Board and Management Team
Suven Pharma Appoints Sudhir Kumar Singh as CEO
Suven Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023
Suven Life Sciences : July 17, 2023Suven Life Announces Clinical and Preclinical data Poster Presentations at AAIC 2023, Amsterdam.
Suven Life Sciences : Form MGT-7 FY 2022-23
Suven Life Sciences : Annual Report FY 2022-23 (Book)
Suven Life Sciences : Annual Report 2022-2023
Suven Life Sciences announces two poster presentations including patient baseline characteristics and demographics from the phase-2 Proof of Concept study on samelisant at the SLEEP-2023 annual meeting
Suven Life Sciences : June 03, 2023Suven announces two poster presentations from the phase-2 (PoC) study on samelisant (SUVN-G3031)
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A1JM5T Aktie
  4. Nachrichten Suven Life Sciences Limited
  5. Andere Sprachen